Free Trial
→ The Death of the Nasdaq? (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:PYXS

Pyxis Oncology Q4 2024 Earnings Report

Pyxis Oncology logo
$2.30 +0.47 (+25.68%)
Closing price 04:00 PM Eastern
Extended Trading
$2.34 +0.04 (+1.91%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pyxis Oncology EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Pyxis Oncology Revenue Results

Actual Revenue
$16.15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pyxis Oncology Announcement Details

Quarter
Q4 2024
Date
3/18/2025
Time
Before Market Opens
Conference Call Date
Tuesday, March 18, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Pyxis Oncology's Q1 2026 earnings is estimated for Friday, May 8, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, May 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Pyxis Oncology's Q4 2024 Press ReleasePress Release
(8-K)
Pyxis Oncology's Q4 2024 Annual reportAnnual report
(10-K)

Pyxis Oncology Earnings Headlines

Wedbush initiates coverage of Pyxis Oncology (PYXS) with outperform recommendation
May 5 at 7:39 PM  |  msn.comhttps://www.msn.com/en-us/health/other/wedbush-initiates-coverage-of-pyxis-oncology-pyxs-with-outperform-recommendation/ar-AA22szNn
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
April 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/17/3276488/0/en/pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-activity-in-a-hnscc-model-with-mamicvo-in-combination-with-anti-pd-1-at-aacr-2026.html
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/23/3260234/0/en/pyxis-oncology-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results.html
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS)
February 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/48337/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-pyxis-oncology-pyxs/
Pyxis Oncology Appoints Thomas Civik as Interim CEO Following Leadership Transition
February 3, 2026  |  quiverquant.comQ
See More Pyxis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email.

About Pyxis Oncology

Pyxis Oncology (NASDAQ:PYXS) (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens. The company’s proprietary conjugation technology is intended to optimize drug‐to‐antibody ratios and stability in circulation, enabling more efficient tumor penetration and payload release. While most programs are currently in preclinical or Phase I development, Pyxis’s strategic approach seeks to address cancers that have historically proven resistant to standard treatments, including triple‐negative breast cancer and certain gastrointestinal malignancies.

Headquartered in Boston, Massachusetts, Pyxis Oncology conducts research and clinical activities across the United States, with plans to expand trials into Europe and Asia as programs advance. The organization draws on expertise from seasoned professionals in oncology drug discovery, translational research and clinical development. Pyxis Oncology continues to collaborate with academic institutions and contract research organizations to accelerate its mission of bringing safer, more effective cancer therapies to patients worldwide.

View Pyxis Oncology Profile
Earnings Tools